Affimed (NASDAQ:AFMD) Given Average Recommendation of “Buy” by Brokerages

Shares of Affimed (NASDAQ:AFMD) have been given a consensus rating of “Buy” by the six research firms that are currently covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $41.67.

A number of analysts have recently weighed in on the stock. Wells Fargo & Company lowered their price target on shares of Affimed from $30.00 to $25.00 and set an “overweight” rating on the stock in a report on Monday, April 1st. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Affimed in a research note on Thursday, June 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a research report on Monday, April 1st. Finally, Laidlaw raised their price objective on Affimed from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, June 13th.

Hedge Funds Weigh In On Affimed

Hedge funds have recently made changes to their positions in the company. EWA LLC purchased a new stake in Affimed during the 4th quarter valued at about $89,000. BNP Paribas Financial Markets lifted its holdings in shares of Affimed by 39.9% during the fourth quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock worth $357,000 after purchasing an additional 163,162 shares during the period. abrdn plc purchased a new stake in Affimed in the fourth quarter valued at approximately $130,000. Finally, Vestal Point Capital LP acquired a new position in Affimed in the 4th quarter worth approximately $341,000. 30.82% of the stock is owned by institutional investors and hedge funds.

Affimed Price Performance

Shares of NASDAQ AFMD opened at $5.41 on Tuesday. Affimed has a 1-year low of $2.23 and a 1-year high of $8.95. The business has a fifty day moving average price of $5.51 and a 200 day moving average price of $5.53. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.06 and a current ratio of 3.06.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.